Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies

Bone Marrow Transplantation

Volumn 20, Issue 1, 1997, Pages 39-43

  Mehta, J ^a,d   Kelsey, S ^b   Chu, P ^c   Powles, R ^a   Hazel, D ^b   Riley, U ^a   Evans, C ^a   Newland, A ^b   Treleaven, J ^a   Singhal, S ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Abelcet; Amphotericin B; Amphotericin B lipid complex; Aspergillosis; Candidiasis; Fungal infection

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CREATININE;

ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD DISEASE; CREATININE BLOOD LEVEL; DRUG EFFICACY; FEMALE; FEVER; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEPHROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; TACHYCARDIA; TACHYPNEA; TREATMENT FAILURE;

EID: 0030857653     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700842     Document Type: Article

References (17)

1. Goodrich JM, Reed EC, Mori M et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164: 731-740.
2. Uzun O, Anaissie EJ. Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood 1995; 86: 2063-2072.
3. Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation Medicine Baltimore 1993; 72: 78-89.
4. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. New Engl J Med 1993; 328: 1323-1332.
5. Bowler WA, Oldfield EC. New approaches to amphotericin B administration. Infect Med 1992; 9: 17-23.
6. Warnock DW. Amphotericin B: an introduction. J Antimicrob Chemother 1991; 28 (Suppl. B): 27-38.
7. Bodey GP, Anaissie EJ, Elting LS et al. Antitungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994; 73: 2099-2106.
8. Bearman SI, Appelbaum FR, Back A et al. Regimen-related toxicity and early post-transplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989; 7: 1288-1294.
9. Glynne P, Powles R, Steele J et al. Renal dysfunction following autologous bone marrow transplantation in adult patients with acute leukemia. Acta Oncol 1996; 35: 709-712.
10. Mehta J. Do variations in molecular structures affect the clinical efficacy and safety of lipid-based amphotericin B preparations? Leuk Res 1997; 21: 183-188.
11. Franklin IM, Mehta J, Root T. The use of amphotericin B lipid complex/ABLC (Ablcet) as an alternative to conventional amphotericin B. J Antimicrob Chemother 1997; 39: 288-290.
12. Powles R, Milan S, Horton C et al. A prospective haematooncology patient database: structure and description. Bone Marrow Transplant 1996; 17 (Suppl. 1): S140.
13. Powles R, Milan S, Horton C et al. A prospective haemato-oncology patient database for use in routine care and clinical research Bone Marrow Transplant 1996; 17 (Suppl. 1): S55.
14. Walsh TJ, Hiemenz JW, Seibel N, Anaissie EJ. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis. Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 1994, Orlando. p 247 (Abstr. M69).
15. Anaissie EJ, White M, Uzun O et al. Amphotericin B lipid complex (ABLC) vs amphotericin B (AMB) for treatment of hematoeenous and invasive candidiasis: a prospective, randomized, multicenter trial. Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 1995, San Francisco, p 330 (Abstr. LM21).
16. Janoff AS, Perkins WR, Saleton SL, Swenson CE. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993; 3: 451-472.
17. Hiemenz JW, Lister J, Anaissie EJ et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical control comparison with amphotericin B. Blood 1995; 86: (Suppl. 1): 849a.